

# Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

## Brilliant Violet 605(TM) anti-human CD56 (NCAM)

RRID:AB\_11142683

Type: Antibody

---

### Proper Citation

BioLegend Cat# 318333, RRID:AB\_11142683

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_11142683](http://antibodyregistry.org/AB_11142683)

**Proper Citation:** BioLegend Cat# 318333, RRID:AB\_11142683

**Target Antigen:** CD56

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** Brilliant Violet 605(TM) anti-human CD56 (NCAM)

**Description:** This monoclonal targets CD56

**Target Organism:** human

**Clone ID:** Clone HCD56

**Antibody ID:** AB\_11142683

**Vendor:** BioLegend

**Catalog Number:** 318333

**Alternative Catalog Numbers:** 318334

**Record Creation Time:** 20250819T234907+0000

**Record Last Update:** 20250820T063040+0000

---

### Ratings and Alerts

- Used for flow cytometry assay by the Human Islet Research Network community.  
Contact(s): [Mark Wallet](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for Brilliant Violet 605(TM) anti-human CD56 (NCAM).

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Fleming AM, et al. (2026) Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumor. Cell reports, 45(3), 117063.

Pedroza LA, et al. (2025) The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity. Cell reports, 44(1), 115156.

Melo Garcia L, et al. (2025) Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells. Cell reports, 44(1), 115122.

Biederst??dt A, et al. (2025) Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency. Cancer cell.

Cook DR, et al. (2025) Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM. Frontiers in immunology, 16, 1579925.

Shanley M, et al. (2024) Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer cell, 42(8), 1450.